Last checked at 
(Alliance News) - Abingdon Health PLC on Monday launched its Covid-19 IgG antibody self-test manufactured in partnership with BioSure Ltd.
Abingdon Health, which signed the exclusive manufacturing agreement with BioSure in July, develops and manufactures rapid lateral flow assay diagnostic tests.
BioSure specialises in the provision of rapid in-vitro diagnostic testing, including self-testing.
The new test is CE marked, meaning it was assessed and deemed to meet EU safety, health and environmental requirements. It uses finger-prick blood and gives results of antibody status in 20 minutes.
The test is in full manufacture at Abingdon Health's York and Doncaster facilities and will be useful in monitoring pre and post-vaccine immunity status, including potential booster vaccinations.
"This initiative allows us to build on our long-term collaboration with the BioSure team for whom we manufacture their HIV self-test in the same format as this new test," said Chief Executive Chris Yates.
"This is the first of several products we have previously noted to be going through the technical transfer process with others for Covid antigen and non-Covid applications to follow and which we expect to contribute to contract manufacturing revenue growth."
The stock was up 29% at 39.39 pence in London on Monday in morning trade, among the best performers on AIM.
By Josie O'Brien; josieobrien@alliancenews.com
Copyright 2021 Alliance News Limited. All Rights Reserved.
